@article {Kawut2102304作者= {Steven m . Kawut和迈克尔·j·Krowka金伯利福德和Nadine Al-Naamani凯伦l . Krok remamta帕特尔和卡罗·r .莎娃玛格丽特•多伊尔和裘德Moutchia林和优雅Jae k哦和卡尔·d·Mottram保罗·d·斯坎伦和迈克尔·b·法伦和肺血管并发症的肝病研究小组},title = {Hepatopulmonary综合症的影响肝移植候选人和血管生成的作用},elocation-id = {2102304} = {2021}, doi ={10.1183/13993003.02304 -2021},出版商={欧洲呼吸学会},文摘= {Hepatopulmonary综合症影响10 {\ textendash} 30 \ %的患者肝硬化和门脉高压。188bet官网地址我们评估hepatopulmonary综合症的血清血管生成配置文件和评估的临床影响hepatopulmonary综合症评估肝移植的病人。肝病的肺血管并发症2研究是一个多中心、前瞻性队列研究的成年人接受他们的第一个肝移植评估。Hepatopulmonary综合征定义为一种alveolar-arterial氧梯度> = 15毫米汞柱(> = 20毫米汞柱如果\ > 64岁),积极的超音波检查发现增强对比度,没有肺部疾病。我们包括85 hepatopulmonary综合症患者和146例无hepatopulmonary综合症。门户hepatopulmonary综合症患者有更多的并发症高血压和终末期肝脏Disease-Na得分略高于模型相比,那些没有hepatopulmonary综合症(中位数(四分位范围)15(12、19)和14 [10、17],p = 0.006)。Hepatopulmonary综合症患者显著降低6分钟步行距离,更糟糕的是功能类。Hepatopulmonary综合症患者有更高的循环angiopoietin-2、Tie2 tenascin-C, c - kit, VCAM-1,和血管性血友病因子水平,降低E-selectin水平。hepatopulmonary综合症患者的死亡风险增加(风险比1.80 1.03 {\ textendash} 3.16, p = 0.04),坚持尽管协变量调整(风险比1.79 1.02 {\ textendash} 3.15, p = 0.04)。这种关联并不随氧化水平反映hepatopulmonary综合症的严重程度。Hepatopulmonary综合症与概要文件相关的异常的系统性血管生成,更糟糕的是运动和功能能力和整体增加死亡的风险。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。 After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Steven M. Kawut has nothing to disclose.Conflict of interest: Michael J. Krowka has nothing to disclose.Conflict of interest: Kimberly A. Forde has nothing to disclose.Conflict of interest: Nadine Al-Naamani has nothing to disclose.Conflict of interest: Karen L. Krok has nothing to disclose.Conflict of interest: Mamta Patel has nothing to disclose.Conflict of interest: Carlo R. Bartoli has nothing to disclose.Conflict of interest: Margaret Doyle has nothing to disclose.Conflict of interest: Jude Moutchia has nothing to disclose.Conflict of interest: Grace Lin has nothing to disclose.Conflict of interest: Jae K. Oh has nothing to disclose.Conflict of interest: Carl D. Mottram has nothing to disclose.Conflict of interest: Paul D. Scanlon has nothing to disclose.Conflict of interest: Michael B. Fallon has nothing to disclose.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2021/12/02/13993003.02304-2021}, eprint = {//www.qdcxjkg.com/content/early/2021/12/02/13993003.02304-2021.full.pdf}, journal = {European Respiratory Journal} }